U.S. PHARMACOPEIA

Search USP29  
Flunisolide
Click to View Image
C24H31FO6·½H2O 443.51

Pregna-1,4-diene-3,20-dione, 6-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, hemihydrate, (6,11,16)-.
6-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone, hemihydrate [77326-96-6].

Anhydrous 434.51 [3385-03-3].
» Flunisolide contains not less than 97.0 percent and not more than 102.0 percent of C24H31FO6, calculated on the anhydrous basis.
Packaging and storage— Preserve in well-closed containers.
Identification—
B: Ultraviolet Absorption 197U
Solution: 10 µg per mL.
Medium: methanol.
Specific rotation 781S: between +103 and +111.
Test solution: 10 mg per mL, in chloroform.
Loss on drying 731 Dry it in vacuum at 60 for 3 hours: it loses not more than 1.0% of its weight.
Water, Method I 921 The anhydrous form contains not more than 1.0%. The hemihydrate form contains between 1.8% and 2.5% (determined on a dried specimen).
Residue on ignition 281: not more than 0.1% from 250 mg.
Chromatographic purity—
Standard solutions— Prepare a solution of USP Flunisolide RS in acetone to contain 10 mg per mL (Standard solution A). Dilute 1 mL of Standard solution A with acetone to 100 mL (Standard solution B).
Test preparation— Prepare a solution of Flunisolide in acetone to contain 10 mg per mL.
Procedure— Apply 10-µL volumes of Standard solution A, Standard solution B, and the Test preparation to a suitable thin-layer chromatographic plate (see Chromatography 621) coated with a 0.25-mm layer of chromatographic silica gel mixture. Place the plate in a suitable chromatographic chamber previously equilibrated with a mixture of toluene and alcohol (90:10), seal the chamber, and develop the chromatogram until the solvent front has moved three-fourths of the length of the plate. Remove the plate, allow the solvent to evaporate, and examine the plate under short-wavelength UV light: the RF value of the principal spot obtained from the Test preparation corresponds to that obtained from Standard solution A. No secondary spot exhibits an intensity greater than that of the principal spot from Standard solution B.
Organic volatile impurities, Method V 467: meets the requirements.
Solvent— Use dimethyl sulfoxide.
Residual solvents 467: meets the requirements.
(Official January 1, 2007)
Assay—
Mobile phase— Prepare a suitable degassed solution of water and acetonitrile (3:2) such that at an approximate flow rate of 1.6 mL per minute, the retention time of Flunisolide is about 6 minutes.
Standard preparation— Dissolve an accurately weighed quantity of USP Flunisolide RS in Mobile phase to obtain a solution having a known concentration of about 0.2 mg per mL.
Assay preparation— Using 20 mg of Flunisolide, accurately weighed, proceed as directed for Standard preparation.
Chromatographic system (see Chromatography 621)—The liquid chromatograph is equipped with a 254-nm detector and a 4-mm × 25-cm column that contains 5- to 10-µm packing L7. The flow rate is about 1.6 mL per minute. Chromatograph the Standard preparation, and record the peak response as directed for Procedure: the column efficiency is not less than 2700 theoretical plates; the tailing factor for the flunisolide peak is not more than 1.7; and the relative standard deviation for replicate injections is not more than 1.0%.
Procedure— Separately inject equal volumes (between 15 µL and 30 µL) of the Standard preparation and the Assay preparation into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the quantity, in mg, of C24H31FO6 in the portion of Flunisolide taken by the formula:
(434.51 / 443.51)100C(rU / rS),
in which 434.51 and 443.51 are the molecular weights of C24H31FO6 and C24H31FO6·½H2O, respectively; C is the concentration, in mg per mL, of USP Flunisolide RS in the Standard preparation; and rU and rS are the peak responses obtained from the Assay preparation and the Standard preparation, respectively.
Auxiliary Information— Staff Liaison : Daniel K. Bempong, Ph.D., Scientist
Expert Committee : (MDPS05) Monograph Development-Pulmonary and Steroids
USP29–NF24 Page 922
Phone Number : 1-301-816-8143